查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844188

人类免疫力缺乏病毒治疗药物市场（依药物类别、治疗方案类型、治疗线、剂型、患者类型和分销管道划分）－2025-2032年全球预测

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人类免疫力缺乏病毒 (HIV) 治疗市场将成长至 293.2 亿美元，复合年增长率为 4.71%。

主要市场统计数据
基准年 2024 202.8亿美元
预计年份：2025年 212.3亿美元
预测年份：2032年 293.2亿美元
复合年增长率 (%) 4.71%

本文首先概述了影响当代爱滋病治疗策略的临床进展、政策发展和相关人员需求，并以此为背景展开论述。

人类免疫力缺乏病毒治疗领域格局的不断演变，需要一个介绍性的框架，将近期临床进展、监管环境和商业性动态纳入一个连贯的策略叙事之中。该框架综合了从抗逆转录病毒联合治疗到当前重点领域（例如长效製剂、简化方案和差异化治疗路径）的科学发展轨迹，同时也承认扩大公平获取途径和降低发病率这一持续存在的公共卫生迫切需求。

此外，引言部分重点阐述了相关人员——临床医生、支付方、生产者和患者权益倡导者——的观点，并着重强调了临床疗效、耐受性和依从性如何影响治疗方法的选择和商业化。引言也强调了治疗方法创新与医疗系统动态之间的相互关係，指出剂型变化和治疗方案复杂性如何直接影响供应链和分销策略。因此，该框架为后续章节深入分析监管趋势、竞争动态和市场细分奠定了基础，从而为决策者提供了所需的背景信息，以便他们优先考虑投资、政策参与和战略伙伴关係。

检验了科学创新、监管变革以及患者和支付方期望的转变为爱滋病治疗带来的变革性变化。

爱滋病治疗领域正经历变革性的转变，这主要得益于科学突破、监管环境的变化以及患者期望的不断提高，这些因素正在重新定义治疗标准和商业性机会。整合酵素抑制剂和长效注射等创新疗法透过提高疗效、耐受性和依从性，正在改变治疗模式，促使製剂研发者和患者优先选择能够减少服药负担并支持持久病毒抑制的治疗方案。

同时，监管核准管道正在调整，以加快核准那些能够显着改善患者依从性和生活品质的产品；而支付方和采购机构则日益重视医疗总成本和基本契约。此外，随着社区主导计画和线上药局的覆盖范围不断扩大，差异化医疗模式和分散式服务模式的日益普及正在重塑分销管道。因此，製药公司必须在创新、可负担性和供应可靠性之间取得平衡，将以患者为中心的临床开发与务实的商业化策略相结合，从而在实现公共卫生目标的同时创造价值。

分析2025年美国关税政策如何改变爱滋病治疗生态系统的供应链、筹资策略和生产决策。

美国2025年实施的关税和贸易措施对爱滋病治疗价值链产生了复杂的影响，波及筹资策略、製造地选择和跨境供应可靠性。製造商和经销商面临利润率和物流成本结构的更大压力，促使许多企业重新评估筹资策略，并探索近岸外包和双重采购模式，以降低关税波动带来的风险。因此，采购负责人和医疗系统面临复杂的合约谈判，需要考虑与关税相关的附加税和更长的交货前置作业时间。

此外，关税政策改变了对国内生产能力和战略储备投资的考量，并加速了关键抗逆转录病毒和重要原料药的韧性和自给自足能力的讨论。为此，一些相关人员加强了与免税国家和地区的契约製造和出口商的合作，而另一些利益相关者则加快了监管协调方面的投资，以简化跨境分销。总而言之，这些相关人员凸显了在贸易中断的情况下，供应链弹性和积极参与知情措施对于维持病患用药和专案连续性的策略必要性。

透过整合药物类别、治疗方案类型、治疗线、剂型、患者类型和分销管道等关键细分洞察，明确您的策略。

精细的细分视角清晰地展现了临床、商业和营运重点的交汇点，为跨产品系列和通路策略的策略决策提供了结构性基础。按药物类别划分，涵盖了入口点抑制剂、整合酶链转移抑制剂、非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂。入口点抑制剂包括恩夫韦地和马拉维罗克；整合酶抑制剂包括比克替拉韦、多替拉韦、埃尔维特格拉韦和拉替拉韦；非核苷类逆转录酶抑制剂包括依非韦伦、依曲韦林、奈韦拉平和利匹韦林；核苷类逆转录酶抑制剂包括阿巴卡韦、恩曲他滨、拉米夫定、替诺福韦和齐多夫定；蛋白酶抑制剂包括阿扎那韦、达芦那韦、福沙那韦和洛匹那韦。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 长效注射抗逆转录病毒疗法在爱滋病治疗的研发和临床试验结果
  • 扩大通用学名药诺福韦艾拉酚胺的取得途径及其对低收入社区可负担性的影响
  • 广谱中和抗体作为被动免疫疗法在爱滋病毒预防和治疗的应用进展
  • 将数位化依从性工具与行动医疗平台整合，以提高高风险族群的抗爱滋病毒疗法依从性
  • 利用潜伏期逆转药物和免疫调节剂靶向HIV病毒库的联合治疗策略研发取得进展
  • First-in-Class衣壳抑制剂在初治患者和经治患者中的监管核准和市场接受度
  • 双药联合治疗策略的出现及其对简化长期爱滋病治疗通讯协定的影响
  • 暴露前预防创新技术（包括长效植入和多用途预防技术）的作用
  • 健康政策转变与全球资金趋势对撒哈拉以南非洲儿童爱滋病药物可近性的影响
  • 利用真实世界证据和患者报告结果评估新型 HIV 疗法的疗效和安全性

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按药物类别分類的人类免疫力缺乏病毒治疗市场

  • 进入抑制剂
    • 恩夫韦地
    • 马拉威罗克
  • 整合酶链转移抑制剂
    • 比克替拉韦
    • 多替拉韦
    • 埃尔维特格拉维尔
    • 拉特格拉维尔
  • 非核苷类逆转录酶抑制剂
    • 依非韦伦
    • 依曲韦林
    • 奈韦拉平
    • 利匹韦林
  • 核苷类逆转录酶抑制剂
    • 阿巴卡韦
    • 恩曲他滨
    • 拉米夫定
    • 替诺福韦
    • 齐多夫定
  • 蛋白酶抑制剂
    • 阿扎那韦
    • 达芦那韦
    • 福沙那韦
    • 洛匹那韦

9. 依治疗方案类型分類的人类免疫力缺乏病毒治疗市场

  • 多药丸疗法
  • 单片服用方案

10. 按治疗线分類的人类免疫力缺乏病毒治疗市场

  • 主要治疗
  • 挽救性治疗
  • 二级治疗

11. 人类免疫力缺乏病毒治疗药物市场（依剂型划分）

  • 注射
  • 口服

12. 依患者类型分類的人类免疫力缺乏病毒治疗市场

  • 成人
  • 孩子们

13. 人类免疫力缺乏病毒治疗药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

14. 各地区人类免疫力缺乏病毒治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 按组别分類的人类免疫力缺乏病毒治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国人类免疫力缺乏病毒治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Gilead Sciences, Inc.
    • ViiV Healthcare Limited
    • Merck & Co., Inc.
    • Janssen Pharmaceutica NV
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Limited
Product Code: MRR-ED54C46E8CF6

The Human Immunodeficiency Virus Therapeutics Market is projected to grow by USD 29.32 billion at a CAGR of 4.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.28 billion
Estimated Year [2025] USD 21.23 billion
Forecast Year [2032] USD 29.32 billion
CAGR (%) 4.71%

Introductory framing that contextualizes clinical advances, policy developments, and stakeholder imperatives shaping contemporary HIV therapeutic strategies

The evolving landscape of human immunodeficiency virus therapeutics demands an introductory framework that situates recent clinical advances, regulatory milestones, and commercial dynamics within a coherent strategic narrative. This introduction synthesizes the scientific trajectory from combination antiretroviral therapy to contemporary priorities such as long-acting formulations, simplified regimens, and differentiated care pathways, while also acknowledging the persistent public health imperative to expand equitable access and reduce morbidity.

Moreover, the introduction clarifies stakeholder perspectives across clinicians, payers, manufacturers, and patient advocates, highlighting how clinical efficacy, tolerability, and real-world adherence shape treatment selection and commercialization. It delineates the interplay between therapeutic innovation and health system capacity, emphasizing how shifts in administration modality and regimen complexity have direct implications for supply chains and distribution strategies. Consequently, this framing sets expectations for deeper sections that analyze regulatory trends, competitive dynamics, and market segmentation, thereby equipping decision-makers with the context needed to prioritize investment, policy engagement, and strategic partnerships.

Examining the major transformative shifts in HIV therapeutics driven by scientific innovation, regulatory change, and evolving patient and payer expectations

The therapeutic landscape for HIV has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing patient expectations, which together are redefining standard-of-care and commercial opportunity. Innovations such as integrase inhibitors and long-acting injectable formulations have altered treatment paradigms by improving potency, tolerability, and adherence profiles, thereby encouraging prescribers and patients to prioritize regimens that reduce pill burden and support sustained viral suppression.

Concurrently, regulatory pathways have adapted to accommodate faster approvals for formulations that demonstrate meaningful improvements in adherence and quality of life, while payers and procurement agencies are increasingly emphasizing total cost of care and outcomes-based contracting. Moreover, the expanded focus on differentiated care models and decentralized delivery is reshaping distribution channels, as community-led programs and online pharmacies amplify reach. As a result, pharmaceutical companies must balance innovation with affordability and supply reliability, integrating patient-centered clinical development with pragmatic commercialization strategies to capture value while advancing public health goals.

Analyzing how the 2025 United States tariff measures reshaped supply chains, procurement strategies, and manufacturing decisions across the HIV therapeutics ecosystem

The imposition of tariffs and trade measures by the United States in 2025 introduced a complex set of effects across the HIV therapeutic value chain, influencing procurement strategies, manufacturing location decisions, and cross-border supply reliability. Manufacturers and distributors experienced increased pressure on margins and logistical cost structures, prompting many to reassess sourcing strategies and to explore nearshoring or dual-sourcing arrangements to mitigate exposure to tariff volatility. Consequently, procurement officers and health systems faced heightened complexity when negotiating contracts that now needed to account for contingent tariff-related surcharges and longer lead times.

Moreover, tariffs altered the calculus for investment in domestic production capacity and strategic stockpiling, accelerating conversations around resilience and self-sufficiency for critical antiretrovirals and key active pharmaceutical ingredients. In response, several stakeholders intensified collaboration with contract manufacturers and exporters in tariff-exempt jurisdictions, while others accelerated investments in regulatory harmonization to streamline cross-border distribution. These adaptive measures, taken together, underscore the strategic necessity of supply chain agility and informed policy engagement to preserve patient access and maintain program continuity amid trade-induced disruption.

Critical segmentation insights that integrate drug class, regimen type, therapy line, administration mode, patient type, and distribution channel for strategic clarity

A granular segmentation lens clarifies where clinical, commercial, and operational priorities converge, providing a structured basis for strategic decision-making across product portfolios and channel strategies. Based on drug class, analysis spans Entry Inhibitors, Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors, with Entry Inhibitors examined through Enfuvirtide and Maraviroc; Integrase inhibitors covered via Bictegravir, Dolutegravir, Elvitegravir, and Raltegravir; Non-Nucleoside reverse transcriptase inhibitors considered through Efavirenz, Etravirine, Nevirapine, and Rilpivirine; Nucleoside reverse transcriptase inhibitors analyzed including Abacavir, Emtricitabine, Lamivudine, Tenofovir, and Zidovudine; and Protease Inhibitors evaluated through Atazanavir, Darunavir, Fosamprenavir, and Lopinavir.

Based on regimen type, the landscape distinguishes between Multi Tablet Regimen and Single Tablet Regimen, recognizing that simplification of dosing remains a central driver of adherence and therapeutic persistence. Based on therapy line, segmentation includes First Line, Salvage Therapy, and Second Line, which informs development priorities for agents intended for treatment-experienced populations or for use where resistance patterns constrain options. Based on mode of administration, the analysis contrasts Injectable and Oral modalities, reflecting the commercial and operational ramifications of long-acting injectables versus daily oral therapies. Based on patient type, differentiation between Adult and Pediatric populations highlights formulation needs, palatability, and dosing considerations that influence pediatric program design. Finally, based on distribution channel, the framework examines Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, recognizing that channel-specific procurement, reimbursement, and adherence support models materially affect uptake and access.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulation, and commercialization strategies

Regional dynamics materially influence clinical adoption, access pathways, and commercial strategies for HIV therapeutics, with each geography presenting distinct regulatory, payer, and delivery considerations. In the Americas, mature regulatory frameworks, established treatment guidelines, and concentrated payer negotiation leverage drive demand for differentiated regimens and outcomes-based contracting, while supply chain complexity necessitates robust distribution partnerships and patient support programs.

Across Europe, Middle East & Africa, heterogeneity in regulatory capacity, procurement models, and health system financing shapes varied adoption patterns; high-income markets prioritize innovation and formulary placement, whereas middle- and low-income settings emphasize affordability, generic competition, and procurement through pooled purchasing mechanisms. In Asia-Pacific, a mix of large domestic manufacturers, progressive regulatory reform in certain jurisdictions, and rapidly evolving private and public payer arrangements create opportunities for localized manufacturing, tiered pricing strategies, and digital health-enabled adherence interventions. Taken together, these regional distinctions underscore the need for tailored commercialization and access strategies that reflect regulatory timelines, procurement structures, and patient population characteristics.

Strategic company-level insights detailing how originators, biotech innovators, generics, and manufacturing partners shape competition and access in HIV therapeutics

Leading companies and strategic entrants each play distinct roles in shaping the HIV therapeutics ecosystem through pipeline investment, partnership models, and manufacturing scale. Originator pharmaceutical firms continue to invest in next-generation molecules, long-acting platforms, and novel delivery systems, leveraging clinical differentiation to pursue premium placements while managing lifecycle strategies against generic erosion. At the same time, biotechnology firms drive innovation with nimble development of first-in-class mechanisms and biologic approaches, frequently collaborating with larger partners to access development expertise and commercial reach.

Generic manufacturers and contract development and manufacturing organizations serve as critical pillars for affordability and supply resilience, particularly in regions where price sensitivity and centralized procurement dominate. Strategic partnerships, licensing agreements, and targeted acquisitions have become common tactics for companies seeking to quickly expand therapeutic breadth or to secure manufacturing capacity. In parallel, technology and digital health companies are increasingly adjacent players, offering adherence support, remote monitoring, and patient engagement solutions that enhance the real-world effectiveness of therapeutics. Together, these actors create an ecosystem where commercial success depends on scientific differentiation, strategic alliances, and the ability to operationalize distribution and patient support at scale.

Practical and actionable recommendations for industry leaders to align therapeutic innovation with resilient supply chains, payer engagement, and patient-centered delivery

Industry leaders should prioritize a suite of actionable strategies that align scientific innovation with supply resilience, payer engagement, and patient-centered delivery models to capture value while improving public health outcomes. First, firms ought to strengthen supply chain diversification by establishing multiple sourcing lanes, qualifying alternative manufacturers, and incorporating contingency inventory practices to guard against trade and logistics disruptions. Second, investment in long-acting formulations and simplified regimens should be paired with targeted evidence generation that demonstrates adherence benefits and health system efficiencies, thereby easing payer acceptance and formulary uptake.

Furthermore, organizations need to actively engage payers and procurement bodies early in development to design value propositions that speak to total cost of care, adherence outcomes, and real-world effectiveness. Concurrently, advancing pediatric-friendly formulations and pragmatic administration models will address persistent access gaps. Companies should also leverage partnerships for local manufacturing or technology transfer where appropriate, enabling tiered pricing and faster market entry. Finally, integrating digital adherence tools and patient support programs into commercialization plans will strengthen therapy persistence and outcomes. These recommendations collectively offer a roadmap for aligning innovation with pragmatic execution across clinical, regulatory, and commercial domains.

Comprehensive research methodology that integrates primary interviews, secondary literature review, and triangulation to validate insights and strategic implications

The research methodology underpinning this analysis combines rigorous primary and secondary approaches to ensure reliability, relevance, and reproducibility of insights. Primary research involved structured interviews and qualitative discussions with a cross-section of clinicians, procurement specialists, payers, key opinion leaders, and industry executives, enabling the capture of real-world perspectives on clinical practice, reimbursement dynamics, and operational constraints. These conversations were designed to surface drivers of treatment choice, barriers to access, and strategic priorities across stakeholder groups.

Secondary research complemented primary inputs through systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to validate clinical and regulatory trends. Data triangulation techniques were applied to reconcile divergent sources and to strengthen confidence in thematic conclusions. Analytical rigor was further enhanced via scenario analysis and sensitivity checks to assess the robustness of strategic implications under varying assumptions. Ethical considerations, including the protection of participant confidentiality and avoidance of commercial bias, were integral to the research process, and limitations related to regional data granularity and rapidly evolving clinical evidence were transparently acknowledged.

Conclusive synthesis emphasizing strategic alignment of clinical innovation, payer engagement, and resilient operations to advance HIV therapeutic access and outcomes

In conclusion, the contemporary HIV therapeutics environment is characterized by meaningful clinical innovation, shifting regulatory and payer expectations, and a heightened focus on supply chain resilience and equitable access. Integrase inhibitors and long-acting modalities exemplify how therapeutic advances can translate into improved adherence and patient experience, while the commercial reality underscores the need for holistic strategies that reconcile innovation with affordability and distribution reliability. Consequently, stakeholders must adopt integrated approaches that bridge clinical differentiation with pragmatic operational execution.

Looking ahead, organizations that successfully align robust evidence generation, proactive payer engagement, and diversified manufacturing and distribution capabilities will be best positioned to deliver both commercial value and public health impact. Continued collaboration across industry, payers, providers, and community organizations will remain essential to translate therapeutic advances into durable improvements in treatment outcomes and access. Ultimately, strategic agility, evidence-based value propositions, and patient-centered delivery models will determine which programs attain sustainable success in this dynamic therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development and clinical trial results of long-acting injectable antiretroviral therapies for HIV management
  • 5.2. Expansion of generic tenofovir alafenamide access and impact on treatment affordability in low-income regions
  • 5.3. Advancement of broadly neutralizing antibodies as passive immunotherapy options for HIV prevention and treatment
  • 5.4. Integration of digital adherence tools and mobile health platforms to enhance ART compliance among high-risk populations
  • 5.5. Pipeline progress of combination cure strategies targeting HIV reservoirs with latency-reversing agents and immune modulators
  • 5.6. Regulatory approval and market uptake of first-in-class capsid inhibitors in treatment-naive and treatment-experienced patients
  • 5.7. Emergence of two-drug regimen strategies and their impact on simplifying long-term HIV therapy protocols
  • 5.8. Role of preexposure prophylaxis innovation including long-acting implants and multipurpose prevention technologies
  • 5.9. Impact of health policy shifts and global funding dynamics on access to pediatric HIV formulations in sub-Saharan Africa
  • 5.10. Adoption of real-world evidence and patient-reported outcomes in evaluating novel HIV therapeutic effectiveness and safety

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Abacavir
    • 8.4.2. Emtricitabine
    • 8.4.3. Lamivudine
    • 8.4.4. Tenofovir
    • 8.4.5. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. Human Immunodeficiency Virus Therapeutics Market, by Regimen Type

  • 9.1. Multi Tablet Regimen
  • 9.2. Single Tablet Regimen

10. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Salvage Therapy
  • 10.3. Second Line

11. Human Immunodeficiency Virus Therapeutics Market, by Mode Of Administration

  • 11.1. Injectable
  • 11.2. Oral

12. Human Immunodeficiency Virus Therapeutics Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Human Immunodeficiency Virus Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Immunodeficiency Virus Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Immunodeficiency Virus Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Gilead Sciences, Inc.
    • 17.3.2. ViiV Healthcare Limited
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Janssen Pharmaceutica NV
    • 17.3.5. Bristol-Myers Squibb Company
    • 17.3.6. Pfizer Inc.
    • 17.3.7. Shionogi & Co., Ltd.
    • 17.3.8. Viatris Inc.
    • 17.3.9. Teva Pharmaceutical Industries Ltd.
    • 17.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MA